*NICE COPD guideline recommendations below are for classes of medicines, not specific products*

NICE recommends the LAMA/LABA class as first-line maintenance therapy in specific COPD patients*1

Are you up-to-date with the NICE guidelines?

LAMA/LABAs are licensed as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.

*In December 2018, NICE updated its guidelines to recommend a LAMA/LABA as first-line maintenance therapy in patients with no asthmatic features/features suggesting steroid responsiveness who remain breathless/have exacerbations despite short acting bronchodilator therapy.

NICE also specifies that such patients should have spirometrically confirmed COPD, have been offered/received treatment for tobacco dependence (if smokers), had optimised non-pharmacological management and received relevant vaccinations.

Click on the image to view NICE's summary (see infographic below) of its COPD recommendations.

© NICE 2019 Chronic obstructive pulmonary disease in over 16s: non-pharmacological management and use of inhaled therapies. Available from www.nice.org.uk/guidance/NG115 All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

For more information on the NICE COPD guidelines see www.nice.org.uk/guidance/NG115

Why did NICE update their recommendation?

The NICE guidelines state that ‘the evidence showed that, compared with other dual therapy combinations and monotherapy, LAMA + LABA:1

Health related quality of life icon

‘Provides the greatest benefit to overall quality of life’1

Icon showing a graph with an upward trend arrow

‘Is better than other inhaled treatments for many individual outcomes…’1

Cost-effectiveness/money icon

‘Is the most cost-effective option’1

Would you like to view the full NICE COPD guidelines?


Hear experts' perspectives on prescribing LAMA/LABA maintenance therapy and listen to real life patient case studies



  1. COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019.Available from: https://www.nice.org.uk/guidance/ng115. Accessed: May 2021.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ .
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.

Innoviva Logo

PM-GB-UCV-WCNT-200035 May 2021